Related Experiment Videos
Phase I study of anguidine administered weekly
Cancer Treatment Reports
|November 1, 1979
Summary
Anguidine treatment in patients showed dose-limiting gastrointestinal and neurologic toxicities. Recommended weekly doses are 6.0 mg/m2 for normal hepatic function and 3.5 mg/m2 for liver dysfunction.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Anguidine is an antineoplastic agent investigated for cancer treatment.
- Understanding anguidine's toxicity profile and optimal dosing is crucial for patient safety and efficacy.
Purpose of the Study:
- To evaluate the safety and tolerability of weekly anguidine administration.
- To determine dose-limiting toxicities and establish recommended starting doses for anguidine therapy.
Main Methods:
- Weekly administration of anguidine to 20 patients.
- Assessment of gastrointestinal, neurologic, and hematologic toxicities.
- Dose escalation or adjustment based on observed toxicities.
Main Results:
- Gastrointestinal and neurologic toxic effects were identified as dose-limiting toxicities for both 4- and 8-hour anguidine infusions.
- Myelosuppression was observed infrequently and was not dose-related.
- Recommended starting doses were established: 6.0 mg/m2 for patients with normal hepatic function and 3.5 mg/m2 for patients with liver dysfunction.
Conclusions:
- Weekly anguidine administration is feasible, with specific dose adjustments needed for patients with hepatic impairment.
- Gastrointestinal and neurologic toxicities are key considerations for anguidine dosing.
- The recommended starting doses provide a guideline for initiating anguidine therapy safely.